Cost-effectiveness of treating deep diabetic foot ulcers with Promogran in four European countries.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Journal of Wound Care

• Publication date

  2002-02-01

• Fields of study

  Medicine, Economics

• Identifiers
  DOI 10.12968/JOWC.2002.11.2.26675PMID 11901743
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cost Effectiveness of Becaplermin in the Treatment of Diabetic Foot Ulcers in Four European Countries

  2012cited by this paper
• The cost-effectiveness of treating diabetic lower extremity ulcers with becaplermin (Regranex): a core model with an application using Swedish cost data.

  2000cited by this paper
• Long-Term Costs for Foot Ulcers in Diabetic Patients in a Multidisciplinary Setting

  1995cited by this paper
• Diabetic foot ulcers in a multidisciplinary setting An economic analysis of primary healing and healing with amputation

  1994cited by this paper
• Markov Models in Medical Decision Making

  1993cited by this paper
• The Dysvascular Foot: A System for Diagnosis and Treatment

  1981cited by this paper

• Inflammation-Modulating Biomedical Interventions for Diabetic Wound Healing: An Overview of Preclinical and Clinical Studies

  2024cites this paper
• Wound pH-Modulating Strategies for Diabetic Wound Healing

  2023cites this paper
• Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Liraglutide 1.8 mg: A Health Economic Analysis in the UK

  2023cites this paper
• Calibration of the IQVIA Core Diabetes Model to the stroke outcomes from the SUSTAIN 6 cardiovascular outcomes trial of once-weekly semaglutide

  2023cites this paper
• Early use of oral semaglutide in the UK: A cost-effectiveness analysis versus continuing metformin and SGLT-2 inhibitor therapy

  2023cites this paper
• Superabsorbent wound dressings versus foams dressings for the management of moderate-to-highly exuding venous leg ulcers in French settings: An early stage model-based economic evaluation.

  2022cites this paper
• Cost-Effectiveness of a Real-Time Continuous Glucose Monitoring System Versus Self-Monitoring of Blood Glucose in People with Type 2 Diabetes on Insulin Therapy in the UK

  2022cites this paper
• The long-term cost-effectiveness of once-weekly semaglutide 1 mg vs. dulaglutide 3 mg and 4.5 mg in the UK

  2022cites this paper
• The clinical efficacy of collagen dressing on chronic wounds: A meta-analysis of 11 randomized controlled trials

  2022cites this paper
• Use of oxidised regenerated cellulose/collagen dressings versus standard of care over multiple wound types: A systematic review and meta‐analysis

  2021cites this paper
• Cost‐effectiveness analysis of superabsorbent wound dressings in patients with moderate‐to‐highly exuding leg ulcers in Germany

  2021cites this paper
• Evaluating the Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Empagliflozin 25 mg for Treatment of Patients with Type 2 Diabetes in the UK Setting

  2021cites this paper
• Cost-effectiveness of TLC-NOSF dressings versus neutral dressings for the treatment of diabetic foot ulcers in France

  2021cites this paper
• Long-term Cost-Effectiveness of Dexcom G6 Real-time Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in Patients With Type 1 Diabetes in the U.K.

  2020cites this paper
• Porcine mesothelium matrix as a biomaterial for wound healing applications

  2020cites this paper
• Effective diabetes complication management is a step toward a carbon-efficient planet: an economic modeling study

  2020cites this paper
• Long-Term Cost-Effectiveness the Dexcom G6 Real-Time Continuous Glucose Monitoring System Compared with Self-Monitoring of Blood Glucose in People with Type 1 Diabetes in France

  2020cites this paper
• Risk assessments and structured care interventions for prevention of foot ulceration in diabetes: development and validation of a prognostic model.

  2020cites this paper
• Assessing the effect of closed-loop insulin delivery from onset of type 1 diabetes in youth on residual beta-cell function compared to standard insulin therapy (CLOuD study): a randomised parallel study protocol

  2020cites this paper
• Processed eggshell membrane powder: Bioinspiration for an innovative wound healing product.

  2019cites this paper
• Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme

  2019cites this paper
• Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16)

  2019cites this paper
• The cost-effectiveness of dulaglutide versus insulin glargine for the treatment of type 2 diabetes mellitus in Japan

  2018cites this paper
• Switching from sitagliptin to liraglutide to manage patients with type 2 diabetes in the UK: A long‐term cost‐effectiveness analysis

  2018cites this paper
• Potential cost-effectiveness of using a collagen-containing dressing in managing diabetic foot ulcers in the UK.

  2018cites this paper
• Evaluation of the long‐term cost‐effectiveness of once‐weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK

  2018cites this paper
• The Cost-effectiveness of Dulaglutide 1.5mg versus Exenatide QW for the Treatment of Patients with Type 2 Diabetes Mellitus in France

  2017cites this paper
• Oxidized Regenerated Cellulose/Collagen Dressings: Review of Evidence and Recommendations

  2017cites this paper
• Evaluation of the long‐term cost‐effectiveness of liraglutide vs lixisenatide for treatment of type 2 diabetes mellitus in the UK setting

  2017cites this paper
• Evaluating the Long-Term Cost-Effectiveness of Daily Administered GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes in the United Kingdom

  2017cites this paper
• Cost-Effectiveness of Liraglutide Versus Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus in the UK

  2017cites this paper
• Current Status and Future of Skin Substitutes for Chronic Wound Healing

  2017cites this paper
• The cost-effectiveness of changes to the care pathway used to identify depression and provide treatment amongst people with diabetes in England: a model-based economic evaluation

  2017cites this paper
• Projected long‐term outcomes in patients with type 1 diabetes treated with fast‐acting insulin aspart vs conventional insulin aspart in the UK setting

  2017cites this paper
• Cost-Effectiveness of Liraglutide Versus Dapagliflozin for the Treatment of Patients with Type-2 Diabetes Mellitus in the UK

  2016cites this paper
• An economic evaluation of chronic wound management in a tertiary hospital

  2016cites this paper
• Prospective and randomised evaluation of the protease‐modulating effect of oxidised regenerated cellulose/collagen matrix treatment in pressure sore ulcers

  2016cites this paper
• Integrated sensor-augmented pump therapy systems [the MiniMed® Paradigm™ Veo system and the Vibe™ and G4® PLATINUM CGM (continuous glucose monitoring) system] for managing blood glucose levels in type 1 diabetes: a systematic review and economic evaluation.

  2016cites this paper
• Long-term health economic benefits of sensor-augmented pump therapy vs continuous subcutaneous insulin infusion alone in type 1 diabetes: a UK perspective

  2016cites this paper
• Development and validation of a cost–utility model for Type 1 diabetes mellitus

  2015cites this paper
• Dressings for Acute and Chronic Wounds

  2015cites this paper
• A systematic review of cost-effectiveness analyses of complex wound interventions reveals optimal treatments for specific wound types

  2015influential citation
• Bioengineering in the oral cavity: our experience

  2013cites this paper
• LEG ULCERS - GOOD RESPONSE TO TREATMENT WITH COLLAGEN, OXIDIZED REGENERATED CELLULOSE AND SILVER MATRIX

  2013cites this paper
• The care of wounds : a guide for nurses

  2012cites this paper
• Advances in the topical treatment of diabetic foot ulcers.

  2012cites this paper
• Management and Prevention of Diabetic Foot Ulcers and Infections

  2012cites this paper
• Cost-utility of exenatide once weekly compared with insulin glargine in patients with type 2 diabetes in the UK

  2011cites this paper
• Small intestinal submucosa and other decellularized matrix biomaterials for tissue repair

  2011cites this paper
• Role of collagen in wound management

  2011cites this paper
• Hard-to-heal wounds: results of an international survey

  2011influential citation
• Effect of Oxidized Regenerated Cellulose/Collagen Matrix on Proteases in Wound Exudate of Patients With Diabetic Foot Ulcers

  2011cites this paper
• Factors Affecting the Healing of Chronic Wounds: An Iconoclastic View

  2010cites this paper
• A review of the literature on topical therapies for diabetic foot ulcers. Part 2: Advanced treatments.

  2009cites this paper
• Cost-effectiveness of insulin detemir compared with neutral protamine Hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in five European countries

  2009cites this paper
• Cost-effectiveness of pioglitazone in type 2 diabetes patients with a history of macrovascular disease: a German perspective

  2009cites this paper
• Cost-effectiveness of pioglitazone in patients with type 2 diabetes and a history of macrovascular disease in a Swiss setting.

  2009cites this paper
• Dressings and topical agents for arterial leg ulcers (Review)

  2009cites this paper
• An economic evaluation of VAC therapy compared with wound dressings in the treatment of diabetic foot ulcers.

  2008cites this paper
• Resource utilization and economic costs of care based on a randomized trial of vacuum-assisted closure therapy in the treatment of diabetic foot wounds.

  2008cites this paper
• Effect of oxidised regenerated cellulose/collagen matrix on proteases in wound exudate of patients with chronic venous ulceration

  2008cites this paper
• The use of PROMOGRANTM to manage a patient suffering radiation damage after a laryngectomy

  2008cites this paper
• Evaluating the cost-effectiveness of therapy conversion to insulin detemir in patients with type 2 diabetes in Germany: a modelling study of long-term clinical and cost outcomes

  2008cites this paper
• Cost impact of blood glucose self-monitoring on complications of type 2 diabetes: a Swiss perspective (ROSSO study No.11).

  2007cites this paper
• Estudio aleatorizado y comparativo de un apósito de colágeno y celulosa oxidada regenerada en el tratamiento de úlceras neuropáticas de pie diabético

  2007cites this paper
• Self-Measurement of Blood Glucose in Patients with Type 2 Diabetes: A Health Economic Assessment

  2007cites this paper
• Estudio aleatorizado y comparativo de un apósito de colágeno y celulosa oxidada regenerada en el tratamiento de úlceras neuropáticas de pie diabético

  2007cites this paper
• Topical oxygen emulsion: a novel wound therapy.

  2007cites this paper
• Transferability of economic evaluations: approaches and factors to consider when using results from one geographic area for another

  2007cites this paper
• [Randomized comparative trial of a collagen/oxidized regenerated cellulose dressing in the treatment of neuropathic diabetic foot ulcers].

  2007cites this paper
• Staphylococcus aureus virulence factors associated with infected skin lesions: influence on the local immune response.

  2007cites this paper
• The Extracellular Matrix in Wound Healing: A Closer Look at Therapeutics for Chronic Wounds

  2007cites this paper
• Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes

  2007cites this paper
• Cellular and Molecular Basis of Impaired Healing of Diabetic Foot Ulcers

  2007cites this paper
• Dressings for acute and chronic wounds: a systematic review.

  2007cites this paper
• What Price Wound Care?

  2006cites this paper
• Cost of type 2 diabetes in Germany over 8 years (the ROSSO study No. 2)

  2006cites this paper
• The molecular biology of chronic wounds and delayed healing in diabetes

  2006cites this paper
• Acarbose in addition to existing treatments in patients with type 2 diabetes: health economic analysis in a German setting

  2006cites this paper
• Expression of matrix metalloproteinases and growth factors in diabetic foot wounds treated with a protease absorbent dressing.

  2006cites this paper
• Thecostandcost-effectivenessofnursingservicesin healthcare

  2005cites this paper
• The cost and cost-effectiveness of nursing services in health care.

  2005cites this paper
• Review of the cost of diabetes complications in Australia, Canada, France, Germany, Italy and Spain

  2005cites this paper
• Proteases and the diabetic foot syndrome: mechanisms and therapeutic implications.

  2005cites this paper
• Use of a protease-modulating matrix in the treatment of pressure sores.

  2005cites this paper
• Promogran and complex surgical lesions: a case report.

  2004cites this paper
• Molekulare Grundlagen der Wundheilung bei diabetischem Fußsyndrom

  2003cites this paper
• [Molecular fundamentals of wound healing in diabetic foot syndrome].

  2003cites this paper
• Dressings and topical agents for arterial leg ulcers.

  2003cites this paper
• Use of an oxidized regenerated cellulose and collagen composite for healing of chronic diabetic foot ulcers: a report of two cases.

  2002cites this paper
• The healing properties of Promogran in venous leg ulcers.

  2002cites this paper
• How a discipline came of age: a history of wound care.

  2002cites this paper
• Next generation products for wound management

  2002cites this paper